Edward K. Koepf

Papers

Total Citations

H-Index

About

Dr. Edward K. Koepf is a leading figure in bioprocess development, with a primary focus on accelerating the timeline for bringing novel monoclonal antibody (mAb) therapeutics from discovery to the clinic. His seminal work, "Leveraging high‐throughput technology to accelerate the time to clinic: A case study of a mAb" (2015, 5 citations), serves as a foundational case study demonstrating how high-throughput cell culture technologies can dramatically compress development schedules. By integrating automated miniaturized bioreactor systems with advanced analytics, Dr. Koepf’s research established a framework for rapid clone selection and process optimization, directly addressing the industry’s critical need to expedite material production for early-phase clinical trials. His contributions have provided a practical roadmap for biopharmaceutical companies seeking to reduce the time-to-clinic for promising therapeutics without compromising product quality. This work has been instrumental in shaping modern high-throughput bioprocess strategies, enabling the efficient progression of an ever-increasing number of novel drug candidates through the development pipeline. Dr. Koepf’s research continues to influence the field, driving innovation in cell culture process intensification and the application of automation to accelerate life-saving therapies to patients.